This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Specific cyanide antidotes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Dicobalt edetate is the treatment of choice for proven cyanide poisoning, but should not be used when the diagnosis is uncertain as in the absence of cyanide, there may be serious side-effects.

Other options include:

  • thiosulphate:
    • sodium salt combines with cyanide under the action of hepatic rhodanase enzyme
    • triggers an osmotic diuresis
    • not very effective when used alone because it penetrates cell membranes more slowly than cyanide

  • nitrites:
    • provide a rapid way of inactivating cyanide by converting a portion of the body's haemoglobin to methaemoglobin - methaemoglobin contains ferric rather than ferrous iron
    • 40% of the body haemoglobin may be converted without serious effects. This represents about 300 g haemoglobin which, theoretically, should chelate 500 mg of cyanide ion
    • inhalation of amyl nitrite is poorly tolerated since only low levels of circulating methaemoglobin are produced before the induction of profound hypotension

  • oxygen - this has a synergistic antidotal action when used in combination with sodium thiosulphate and sodium nitrite.

  • hydroxocobalamin:
    • chelates to form cyanocobalamin
    • complex is excreted renally
    • high concentrations are required and effect is limited

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.